PMID- 29348904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 68
DP  - 2017 Dec 22
TI  - Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 
      in psychological stress and depression.
PG  - 113258-113268
LID - 10.18632/oncotarget.19935 [doi]
AB  - Major depressive disorder is a common illness worldwide, but the pathogenesis of 
      the disorder remains incompletely understood. The tissue-type plasminogen 
      activator-plasminogen proteolytic cascade is highly expressed in the brain 
      regions involved in mood regulation and neuroplasticity. Accumulating evidence 
      from animal and human studies suggests that tissue-type plasminogen activator and 
      its chief inhibitor, plasminogen activator inhibitor-1, are related to stress 
      reaction and depression. Furthermore, the neurotrophic hypothesis of depression 
      postulates that compromised neurotrophin brain-derived neurotrophic factor (BDNF) 
      function is directly involved in the pathophysiology of depression. In the brain, 
      the proteolytic cleavage of proBDNF, a BDNF precursor, to mature BDNF through 
      plasmin represents one mechanism that can change the direction of BDNF action. We 
      also discuss the implications of tissue-type plasminogen activator and 
      plasminogen activator inhibitor-1 alterations as biomarkers for major depressive 
      disorder. Using drugs that increase tissue-type plasminogen activator or decrease 
      plasminogen activator inhibitor-1 levels may open new avenues to develop 
      conceptually novel therapeutic strategies for depression treatment.
FAU - Tsai, Shih-Jen
AU  - Tsai SJ
AD  - Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170804
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5762589
OTO - NOTNLM
OT  - brain-derived neurotrophic factor
OT  - major depressive disorder
OT  - plasminogen activator inhibitor-1
OT  - stress
OT  - tissue-type plasminogen activator
COIS- CONFLICTS OF INTEREST The author has no other potential conflict of interest to 
      disclose.
EDAT- 2018/01/20 06:00
MHDA- 2018/01/20 06:01
PMCR- 2017/12/22
CRDT- 2018/01/20 06:00
PHST- 2017/05/30 00:00 [received]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2018/01/20 06:00 [entrez]
PHST- 2018/01/20 06:00 [pubmed]
PHST- 2018/01/20 06:01 [medline]
PHST- 2017/12/22 00:00 [pmc-release]
AID - 19935 [pii]
AID - 10.18632/oncotarget.19935 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 4;8(68):113258-113268. doi: 10.18632/oncotarget.19935. 
      eCollection 2017 Dec 22.